Sormani MP, Häring DA, Kropshofer H, et al. Blood NfL as a potential endpoint in Phase 2 clinical studies in relapsing-remitting multiple sclerosis. ECTRIMS 2017, 277.
Ocrelizumab bij relapsing en primair progressieve MS
jan 2017 | Multipele Sclerose